OECD Book: Innovation in Pharmaceutical Biotechnology - Comparing National Innovation Systems at the Sectoral Level (link)

April 11, 2006

Paris, 10 Apr 2006

What are the specific characteristics of innovation in pharmaceutical biotechnology? How do biopharmaceutical innovation systems in OECD countries perform and which policies are suitable to foster performance?

This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries: Belgium, Finland, France, Germany, Japan, the Netherlands, Norway and Spain. The report summarises the results of in-depth studies, providing a comparative analysis of participating countries' performance in science and innovation in biopharmaceuticals. It highlights specific characteristics of the national biopharmaceutical innovation systems in terms of their international openness and the specific role of demand-side factors in the innovation process. Major systemic failures affecting the functioning of the biopharmaceutical innovation systems are identified. Based on rich evidence, the report draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.

This study forms part of a larger effort to compare innovation processes in different industry sectors and technological fields to provide policy guidance and to more fully elaborate the national innovation systems (NIS) approach to policy making.

Table of contents


Executive Summary (English) - available for free download

Note de synthèse (French) - available for free download

  • Chapter 1. Introduction

  • Chapter 2. Summary of Country Studies:
    • Belgium
    • Finland
    • France
    • Germany
    • Japan
    • The Netherlands
    • Norway
    • Spain
  • Chapter 3. Comparison of Performance in National Biopharmaceutical Innovation Systems

  • Chapter 4. Openness of the Biopharmaceutical Innovation System

  • Chapter 5. Comparison of Selected Demand-side Factors

  • Chapter 6. Structure, Dynamics and Performance in National Biopharmaceutical Innovation Systems

  • Chapter 7. Systemic Imperfections in Biopharmaceutical Innovation Systems

  • Chapter 8. Policy Implications
  • The full volume can be browsed on the OECD Online Bookshop.

    Further information

    Organisation for Economic Co-operation and Development
    Item source

    You've reached your article limit

    Register to continue

    Registration is free and only takes a moment. Once registered you can read a total of 6 articles each month, plus:

    • Sign up for the editor's highlights
    • Receive World University Rankings news first
    • Get job alerts, shortlist jobs and save job searches
    • Participate in reader discussions and post comments

    Have your say

    Log in or register to post comments

    Most Commented

    Home secretary says government will support 'best' universities

    Man handing microphone to audience member

    Academic attainment of disadvantaged students can be improved if they can decide how they are assessed, study claims

    Woman drinking tea from saucer

    Plugging a multibillion-pound deficit exacerbated by June’s poll result may require ‘drastic measures’, analysts have warned

    Italy's gold medallist

    New measures to ensure universities are ‘not penalised’ for taking poorer students also outlined for next stage of TEF

    Classroom, school

    Higher education institutions can and should do more to influence education at a secondary school level, says Edward Peck